IDF via flickr
This is one of Novo Nordisk's biggest manufacturing investments to date.
The new facility will produce injectable medications for obesity and other severe chronic conditions. It will be roughly 1.4 million square feet (130,000 square meters) in size, which is almost equal to the total area of the company's three current facilities in North Carolina. It will also generate 1,000 jobs.
The completion of the construction is slated for 2027–2029.
Compared to $3.9 billion the previous year, Novo Nordisk has increased its facility investment commitment to $6.8 billion for the full year 2024.
source: bloomberg.com
The new facility will produce injectable medications for obesity and other severe chronic conditions. It will be roughly 1.4 million square feet (130,000 square meters) in size, which is almost equal to the total area of the company's three current facilities in North Carolina. It will also generate 1,000 jobs.
The completion of the construction is slated for 2027–2029.
Compared to $3.9 billion the previous year, Novo Nordisk has increased its facility investment commitment to $6.8 billion for the full year 2024.
source: bloomberg.com
